Bone Marrow Transplant in India: Complete Guide for International Patients 2026
Bone Marrow Transplant in India: Complete Guide for International Patients 2026
India now performs over 2,000 bone marrow transplant procedures annually — a figure that continues to grow as the country's haematology infrastructure expands and international patients discover what Indian BMT centres offer: world-class outcomes, experienced multidisciplinary teams, and costs that are 70–80% lower than the USA or Europe.
For patients from Africa — many of whom face leukaemia, thalassaemia, or aplastic anaemia without access to transplant-capable centres in their home countries — India represents the most accessible path to a potentially curative treatment. This is the complete guide to the BMT process, costs, donor options, and top centres in India in 2026.
What Is a Bone Marrow Transplant?
A bone marrow transplant (BMT) — more precisely called a haematopoietic stem cell transplant (HSCT) — replaces diseased or damaged blood-forming stem cells with healthy ones. The "new" stem cells travel to the bone marrow, engraft, and begin producing healthy blood cells for the rest of the patient's life.
BMT can be curative for diseases that would otherwise be fatal: acute leukaemias, aplastic anaemia, thalassaemia, sickle cell disease, and certain lymphomas. It is one of the most demanding medical procedures available — physically, logistically, and financially — but for many patients it is the only treatment with curative potential.
Types of Bone Marrow Transplant
Autologous transplant uses the patient's own stem cells. Before high-dose chemotherapy is given to destroy the disease, doctors harvest and freeze stem cells from the patient's peripheral blood (via apheresis after G-CSF stimulation). After conditioning chemotherapy, the cells are reinfused to restore the blood system. Because the cells are the patient's own, there is no rejection risk and no graft-versus-host disease (GvHD). Autologous BMT is used for multiple myeloma, Hodgkin lymphoma, and certain non-Hodgkin lymphomas.
Cost in India: $15,000–25,000.
Allogeneic transplant uses stem cells from a donor — ideally a fully HLA-matched sibling (the gold standard), but also an unrelated matched donor from a registry or a haploidentical (half-matched) family member. Donor immune cells provide a graft-versus-tumour (GvT) effect that helps eliminate residual leukaemia — the key advantage of allogeneic over autologous for haematological malignancies. The trade-off is risk of GvHD and longer, more immunosuppressed recovery.
Cost in India: $20,000–40,000, depending on donor type.
Haploidentical transplant allows transplant from a half-matched donor — parent to child, child to parent, or sibling with 5/10 HLA match. Modern protocols using post-transplant cyclophosphamide (PTCy) have transformed outcomes: GvHD rates now approach those seen in matched sibling transplants at experienced centres. Almost every patient has a haploidentical donor, making this the fastest option when time is critical. Cost: similar to standard allogeneic BMT.
Conditions Treated with BMT in India
| Condition | Transplant Type | Notes |
|---|---|---|
| Acute myeloid leukaemia (AML) | Allogeneic | First or second remission; MRD status guides decision |
| Acute lymphoblastic leukaemia (ALL) | Allogeneic | High-risk features or Ph+ disease |
| Chronic myeloid leukaemia (CML) | Allogeneic | Tyrosine kinase inhibitor failure or blast crisis |
| Hodgkin lymphoma (relapsed) | Autologous | After salvage chemotherapy |
| Non-Hodgkin lymphoma (relapsed) | Autologous | Specific histologies; allogeneic for some |
| Multiple myeloma | Autologous | After induction; part of standard treatment sequence |
| Aplastic anaemia | Allogeneic | First-line for young patients with matched sibling |
| Thalassaemia major | Allogeneic | Curative option before iron overload causes organ damage |
| Sickle cell disease (severe) | Allogeneic | Increasingly offered; curative when successful |
| MDS (Myelodysplastic Syndrome) | Allogeneic | High-risk disease progressing to AML |
Thalassaemia and sickle cell disease deserve particular mention for African patients. Sickle cell disease affects millions across sub-Saharan Africa and causes progressive organ damage, stroke, and early death without definitive treatment. Haematopoietic stem cell transplant is curative for sickle cell disease — and India's centres have growing experience with this indication.
Top BMT Centres in India
AIIMS, Delhi — India's premier public academic medical institution. Its haematology department trains the country's next generation of transplant haematologists and handles the full spectrum of BMT indications, including rare haematological conditions. AIIMS has particular expertise in thalassaemia and sickle cell transplantation, with outcomes published in peer-reviewed literature. For patients who need public-sector pricing, AIIMS is the best available option.
Christian Medical College (CMC), Vellore — One of Asia's most respected academic medical centres. CMC's haematology unit has decades of BMT experience and is particularly noted for outcomes in thalassaemia and aplastic anaemia. International patients benefit from English-language care and a long tradition of serving patients from across South and Southeast Asia and Africa.
Tata Memorial Hospital, Mumbai — India's leading cancer centre by volume. The haematology and BMT programme at Tata Memorial handles the country's largest caseload of leukaemia transplants. Published data shows outcomes consistent with international benchmarks. As a government-supported institution, costs are substantially lower than private hospitals.
Apollo Hospitals (Delhi, Chennai) — JCI-accredited private hospitals with dedicated BMT units, international patient coordinators, and experienced haematology teams including consultants with training at European and US transplant centres. The private-hospital environment, English-language records, and end-to-end support make Apollo a natural first choice for international patients prioritising comfort and administrative ease alongside clinical quality.
Fortis Memorial Research Institute, Gurugram and Max Super Speciality Hospital, Delhi round out the tier-one private sector options, each with modern HEPA-filtered BMT units and experienced teams in autologous and allogeneic transplants.
HLA Matching: The Donor Question
The donor question is often the most stressful part of the BMT journey. A full 10-allele HLA match is ideal for allogeneic transplant. Here is the realistic picture for each donor pathway:
Matched sibling donor: The gold standard. A fully HLA-identical sibling achieves the best outcomes and the fastest timeline. Approximately 25–30% of patients will have a matched sibling. HLA typing results are available in 1–2 weeks.
Unrelated matched donor: Registry search through the Indian Bone Marrow Registry (IBMR, 500,000+ donors) and international registries (NMDP in the USA, WMDA-linked registries in Europe). Search results take 4–8 weeks. Match rates depend on ethnicity — patients of African ancestry face lower registry match rates due to underrepresentation, though this is improving.
Haploidentical donor: Available to almost every patient. Parent, child, or non-identical sibling. With modern PTCy protocols, outcomes at experienced centres are approaching matched sibling results. For patients without a matched sibling and urgent timelines, haploidentical is often the fastest path to transplant.
The BMT Process Week by Week
Understanding the timeline reduces uncertainty.
Weeks 1–2 (Pre-transplant evaluation): Bone marrow biopsy, HLA typing, full organ function assessment (cardiac echo, lung function, liver and kidney tests, infection screens). This establishes transplant eligibility and identifies risks.
Weeks 2–3 (Conditioning chemotherapy): High-dose chemotherapy (myeloablative or reduced-intensity depending on patient age and fitness) destroys the diseased marrow and suppresses the immune system. The patient is already in the isolation ward.
Day 0 (The transplant): Stem cells are infused via a central line. The procedure takes a few hours. This is the calendar anchor point — all subsequent days are numbered from day 0.
Days 1–28 (Engraftment period): Stem cells travel to the marrow and begin producing blood cells. This is the most vulnerable period — near-zero immune function. HEPA-filtered positive-pressure isolation rooms prevent environmental infection. Daily blood count monitoring.
Days 28–60 (Post-engraftment monitoring): Transition from isolation to monitored outpatient status. Watch for acute GvHD, infection, and organ complications. Immunosuppressive medications tapered gradually.
Weeks 8–12 (Discharge preparation): When counts are stable and no active complications, patients are cleared to fly home. Detailed post-transplant instructions and a telemedicine connection to the Indian BMT team are established before departure.
Post-BMT Telemedicine Follow-Up
Full immune reconstitution after allogeneic transplant takes 12–24 months. During this period, regular monitoring is essential: blood counts, chimerism testing (to confirm donor engraftment), tacrolimus or cyclosporine levels (immunosuppression monitoring), CMV and EBV surveillance.
Arodya connects patients returning to Africa with the telemedicine infrastructure to make this follow-up real. Blood tests done locally are uploaded to a shared portal reviewed by the Indian BMT team. Video consultations are held regularly. Local physician updates are coordinated. The goal is continuity of expert oversight even after the patient is home.
Starting Your BMT Journey with Arodya
Submit your case through our intake form with your diagnosis, recent blood counts, bone marrow biopsy report, and prior treatment history. Arodya's haematology coordinator reviews your case and provides a hospital recommendation and cost estimate within 3–5 days.
For patients wanting to understand the full cost landscape, our cancer treatment cost comparison guide — India vs USA vs UK puts BMT costs in broader context.
BMT is demanding. It is also curative for conditions that otherwise have no cure. India's transplant centres have the volume, the expertise, and the pricing to make it possible for international patients — and Arodya makes the journey navigable.
